{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T18:28:24Z","timestamp":1693420104097},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00108-019-0618-3","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T20:13:52Z","timestamp":1558556032000},"page":"684-689","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pilzinfektionen"],"prefix":"10.1007","volume":"60","author":[{"given":"P.","family":"K\u00f6hler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"618_CR1","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.healun.2018.06.008","volume":"37","author":"CA Aguilar","year":"2018","unstructured":"Aguilar CA, Hamandi B, Fegbeutel C et\u00a0al (2018) Clinical risk factors for invasive aspergillosis in lung transplant recipients: results of an international cohort study. J\u00a0Heart Lung Transpl 37:1226\u20131234","journal-title":"J Heart Lung Transpl"},{"key":"618_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13543","author":"JW Baddley","year":"2019","unstructured":"Baddley JW, Forrest GN, Practice ASTIDCo (2019) Cryptococcosis in Solid Organ Transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant: e13543. https:\/\/doi.org\/10.1111\/ctr.13543","journal-title":"Clin Transplant"},{"key":"618_CR3","volume-title":"Deutsch-\u00d6sterreichische Leitlinien zur Therapie und Prophylaxe opportunistischer Infektionen bei HIV-infizierten erwachsenen Patienten","author":"C Boesecke","year":"2014","unstructured":"Boesecke C, Grabmeier-Pfistershammer K, Hahn K et al (2014) Deutsch-\u00d6sterreichische Leitlinien zur Therapie und Prophylaxe opportunistischer Infektionen bei HIV-infizierten erwachsenen Patienten (AWMF-Register-Nr.\u00a0055-006)"},{"key":"618_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1200\/JCO.2001.19.1.253","volume":"19","author":"D Caillot","year":"2001","unstructured":"Caillot D, Couaillier JF, Bernard A et\u00a0al (2001) Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J\u00a0Clin Oncol 19:253\u2013259","journal-title":"J Clin Oncol"},{"key":"618_CR5","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1128\/AAC.05134-11","volume":"55","author":"OA Cornely","year":"2011","unstructured":"Cornely OA, Vehreschild JJ, Vehreschild MJ et\u00a0al (2011) Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother 55:5798\u20135803","journal-title":"Antimicrob Agents Chemother"},{"key":"618_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.fgb.2015.02.009","volume":"78","author":"F Hagen","year":"2015","unstructured":"Hagen F, Khayhan K, Theelen B et\u00a0al (2015) Recognition of seven species in the Cryptococcus gattii\/Cryptococcus neoformans species complex. Fungal Genet Biol 78:16\u201348","journal-title":"Fungal Genet Biol"},{"key":"618_CR7","doi-asserted-by":"crossref","first-page":"20262","DOI":"10.2807\/ese.17.36.20262-en","volume":"17","author":"A Hamprecht","year":"2012","unstructured":"Hamprecht A, Buchheidt D, Vehreschild JJ et al (2012) Azole-resistant invasive aspergillosis in a\u00a0patient with acute myeloid leukaemia in Germany. Euro Surveill 17:20262","journal-title":"Euro Surveill"},{"key":"618_CR8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/cid\/civ103","volume":"60","author":"L Heylen","year":"2015","unstructured":"Heylen L, Maertens J, Naesens M et al (2015) Invasive aspergillosis after kidney transplant: case-control study. Clin Infect Dis 60:1505\u20131511","journal-title":"Clin Infect Dis"},{"key":"618_CR9","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1345\/aph.1L243","volume":"42","author":"A Howard","year":"2008","unstructured":"Howard A, Hoffman J, Sheth A (2008) Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 42:1859\u20131864","journal-title":"Ann Pharmacother"},{"key":"618_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.idc.2015.10.003","volume":"30","author":"P Koehler","year":"2016","unstructured":"Koehler P, Cornely OA (2016) Contemporary strategies in the prevention and management of fungal infections. Infect Dis Clin North Am 30:265\u2013275","journal-title":"Infect Dis Clin North Am"},{"key":"618_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.10.019","author":"P Koehler","year":"2016","unstructured":"Koehler P, Hamprecht A, Bader O et\u00a0al (2016) Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. Int J Antimicrob Agents 49(2):218\u2013223. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.10.019 . Epub 2016 Dec 12","journal-title":"Int J Antimicrob Agents"},{"key":"618_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12165","author":"P Koehler","year":"2014","unstructured":"Koehler P, Tacke D, Cornely OA (2014) Aspergillosis of bones and joints\u2014a\u00a0review from 2002 until today. Mycoses 57(6):323\u2013335. https:\/\/doi.org\/10.1111\/myc.12165 . Epub 2014 Jan 8","journal-title":"Mycoses"},{"key":"618_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA et al (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a\u00a0phase 3, randomised-controlled, non-inferiority trial. Lancet 387:760\u2013769","journal-title":"Lancet"},{"key":"618_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1086\/339202","volume":"34","author":"KA Marr","year":"2002","unstructured":"Marr KA, Carter RA, Crippa F et\u00a0al (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909\u2013917","journal-title":"Clin Infect Dis"},{"key":"618_CR15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, Ostrosky-Zeichner L, Cornely OA et al (2016) Isavuconazole treatment for mucormycosis: a\u00a0single-arm open-label trial and case-control analysis. Lancet Infect Dis 16:828\u2013837","journal-title":"Lancet Infect Dis"},{"key":"618_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1055\/s-0035-1562892","volume":"36","author":"MH Miceli","year":"2015","unstructured":"Miceli MH, Maertens J (2015) Role of non-culture-based tests, with an emphasis on Galactomannan testing for the diagnosis of invasive Aspergillosis. Semin Respir Crit Care Med 36:650\u2013661","journal-title":"Semin Respir Crit Care Med"},{"key":"618_CR17","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.30.30300","author":"J van Paassen","year":"2016","unstructured":"van Paassen J, Russcher A, in \u2019t Veld-van Wingerden AW, Verweij PE, Kuijper EJ (2016) Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an intensive care unit in the Netherlands, 2010 to 2013. Euro Surveill 21:(30). https:\/\/doi.org\/10.2807\/1560-7917.ES.2016.21.30.30300","journal-title":"Euro Surveill"},{"key":"618_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1086\/322597","volume":"33","author":"PG Pappas","year":"2001","unstructured":"Pappas PG, Perfect JR, Cloud GA et al (2001) Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 33:690\u2013699","journal-title":"Clin Infect Dis"},{"key":"618_CR19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW et\u00a0al (2016) Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the infectious diseases society of america. Clin Infect Dis 63:e1\u2013e60","journal-title":"Clin Infect Dis"},{"key":"618_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/649858","volume":"50","author":"JR Perfect","year":"2010","unstructured":"Perfect JR, Dismukes WE, Dromer F et\u00a0al (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 50:291\u2013322","journal-title":"Clin Infect Dis"},{"key":"618_CR21","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1086\/503427","volume":"42","author":"CD Pfeiffer","year":"2006","unstructured":"Pfeiffer CD, Fine JP, Safdar N (2006) Diagnosis of invasive aspergillosis using a\u00a0galactomannan assay: a\u00a0meta-analysis. Clin Infect Dis 42:1417\u20131727","journal-title":"Clin Infect Dis"},{"key":"618_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s15010-008-8124-x","volume":"37","author":"M Rosenhagen","year":"2009","unstructured":"Rosenhagen M, Feldhues R, Schmidt J et\u00a0al (2009) A risk profile for invasive aspergillosis in liver transplant recipients. Infection 37:313\u2013319","journal-title":"Infection"},{"key":"618_CR23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/myc.12838","volume":"61","author":"M Ruhnke","year":"2018","unstructured":"Ruhnke M, Behre G, Buchheidt D et\u00a0al (2018) Diagnosis of invasive fungal diseases in haematology and oncology: 2018 update of the recommendations of the infectious diseases working party of the German society for hematology and medical oncology (AGIHO). Mycoses 61:796\u2013813","journal-title":"Mycoses"},{"key":"618_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/myc.12631","volume":"60","author":"D Seidel","year":"2017","unstructured":"Seidel D, Duran Graeff LA, Vehreschild M et\u00a0al (2017) Fungiscope()\u2014global emerging fungal infection registry. Mycoses 60:508\u2013516","journal-title":"Mycoses"},{"key":"618_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/bmt.2009.203","volume":"45","author":"VR Shannon","year":"2010","unstructured":"Shannon VR, Andersson BS, Lei X et\u00a0al (2010) Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant 45:647\u2013655","journal-title":"Bone Marrow Transplant."},{"key":"618_CR26","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/jac\/dku566","volume":"70","author":"J Steinmann","year":"2015","unstructured":"Steinmann J, Hamprecht A, Vehreschild MJ et al (2015) Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J\u00a0Antimicrob Chemother 70:1522\u20131526","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"618_CR27","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S et al (2018) Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 24(Suppl 1):e1\u2013e38","journal-title":"Clin Microbiol Infect"},{"key":"618_CR28","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1007\/s00330-016-4717-4","volume":"27","author":"JJ Vehreschild","year":"2017","unstructured":"Vehreschild JJ, Heussel CP, Groll AH et\u00a0al (2017) Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis. Eur Radiol 27:3275\u20133282","journal-title":"Eur Radiol"},{"key":"618_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","volume":"21\u201322","author":"PE Verweij","year":"2015","unstructured":"Verweij PE, Ananda-Rajah M, Andes D et al (2015) International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat 21\u201322:30\u201340","journal-title":"Drug Resist Updat"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0618-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-0618-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0618-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T12:34:54Z","timestamp":1663504494000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-0618-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-0618-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]},"assertion":[{"value":"22 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0K\u00f6hler hat unabh\u00e4ngig von der eingereichten Arbeit unentgeltliche Forschungsunterst\u00fctzung von Miltenyi Biotec GmbH, Bergisch Gladbach, und dem Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Universit\u00e4t zu K\u00f6ln, K\u00f6ln, erhalten. Er hat Vortragshonorare von der Akademie f\u00fcr Infektionsmedizin e.\u202fV., Astellas Pharma, Gilead Sciences und MSD Sharp & Dohme GmbH erhalten. O.A.\u00a0Cornely hat unabh\u00e4ngig von der eingereichten Arbeit Forschungsmittel erhalten von Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Medicines Company, Medpace, Melinta Therapeutics, Merck\/MSD, Pfizer und Scynexis, ist f\u00fcr Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, IQVIA, Matinas, Medpace, Menarini Ricerche, Merck\/MSD, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase und Vical beratend t\u00e4tig und hat Vortragshonorare von Astellas, Basilea, Gilead, Merck\/MSD und Pfizer bezogen. J.J.\u00a0Vehreschild hat Honorare von folgenden Firmen\/Einrichtungen erhalten: Merck\/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, Deutsches Zentrum f\u00fcr Infektionsforschung, Uniklinik Freiburg\/Kongress und Kommunikation, Akademie f\u00fcr Infektionsmedizin, Universit\u00e4t Manchester, Deutsche Gesellschaft f\u00fcr Infektiologie, \u00c4rztekammer Nordrhein, Uniklinik Aachen, Back Bay Strategies, Deutsche Gesellschaft f\u00fcr Innere Medizin. Er hat Forschungsstipendien von Merck\/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, dem Deutschen Zentrum f\u00fcr Infektionsforschung und Bundesministerium f\u00fcr Bildung und Forschung erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}